Tris Pharma Initiates ALLEVIATE-1 and ALLEVIATE-2, Pivotal Phase 3 Trials Investigating Cebranopadol, a First-in-Class Compound with a Novel Mechanism of Action to Treat Pain (Businesswire) - Aug 21, 2024 - "Tris Pharma, Inc...announced today the initiation of ALLEVIATE-1 and ALLEVIATE-2, pivotal Phase 3 trials evaluating the efficacy and safety of cebranopadol for the treatment of moderate-to-severe acute pain....Together, the studies will enroll more than 500 patients at clinical trial sites in the United States. The results of these registrational studies will be part of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of cebranopadol."
Trial status • Pain
|